CAJ | 학술논문

目的：对孟鲁司特联合吸入沙美特罗替卡松治疗支气管哮喘的临床疗效进行探讨。方法：选取我院于2013年2月至2014年2月收治的37名支气管哮喘患者为研究对象，随机将其分为两组，分别为研究组和对照组，研究组有18例，对照组19例，研究组患者采用口服孟鲁司特联合吸入沙美特罗替卡松进行治疗，孟鲁司特的剂量为10mg，一天一次，吸入沙美特罗替卡松的剂量为50μg/250μg，一天一次；对照组采用沙美特罗替卡松进行治疗，剂量为50μg/250μg，一天两次。主要对患者的ACT （哮喘控制测试情况）、（PEF）呼气峰值流速进行检测和记录，并观察患者用药后的不良反应。结果：经过试验，研究组的18名患者和对照组的19名患者的ACT、PEF情况的差异不具有统计学意义，两组患者的哮喘症状均得到良好的控制，肺功能得到了明显的改善，两组的临床治疗效果均十分良好，差异不具有统计学意义。结论：采用孟鲁司特联合沙美特罗替卡松对支气管哮喘进行治疗，口服前者，吸入小剂量后者，所得临床疗效与沙美特罗替卡松的常规剂量治疗的差异不具有统计学意义，具有同样的安全有效性。
목적：대맹로사특연합흡입사미특라체잡송치료지기관효천적림상료효진행탐토。방법：선취아원우2013년2월지2014년2월수치적37명지기관효천환자위연구대상，수궤장기분위량조，분별위연구조화대조조，연구조유18례，대조조19례，연구조환자채용구복맹로사특연합흡입사미특라체잡송진행치료，맹로사특적제량위10mg，일천일차，흡입사미특라체잡송적제량위50μg/250μg，일천일차；대조조채용사미특라체잡송진행치료，제량위50μg/250μg，일천량차。주요대환자적ACT （효천공제측시정황）、（PEF）호기봉치류속진행검측화기록，병관찰환자용약후적불량반응。결과：경과시험，연구조적18명환자화대조조적19명환자적ACT、PEF정황적차이불구유통계학의의，량조환자적효천증상균득도량호적공제，폐공능득도료명현적개선，량조적림상치료효과균십분량호，차이불구유통계학의의。결론：채용맹로사특연합사미특라체잡송대지기관효천진행치료，구복전자，흡입소제량후자，소득림상료효여사미특라체잡송적상규제량치료적차이불구유통계학의의，구유동양적안전유효성。
Objective: to montelukast combined with inhaled salmeterol and fluticasone propionate in the treatment of bronchial asthma: a clinical efficacy study. Method: selected February 2013 to February 2014 admitted of 37 name bronchial asthma pa-tients for research object, random will its is divided into two group, respectively for research group and control group, research group has 18 cases, control group 19 cases, research group patients used oral Menruster Division special joint inhalation sand beauty special Luo on behalf of Casson for treatment, Menruster Division special of dose for 10mg, a days a times, inhalation sand beauty special Luo on behalf of Casson of dose for 50μg/250μg, a days a times;Controls use of salmeterol and fluticasone propionate treatment, dose of 50μg/250μg, twice a day. The ACT primarily to patients (asthma control test) , (PEF) to detect and record the peak expiratory flow rate, and observation of patients with adverse reactions after administration. Results: after testing, 18 patients of the study group and control group of 19 patients ACT, no statistically significant difference between PEF situations, two groups of patients with asthma symptoms are well controlled, has been significantly improved lung function and clinical effect of the two group are very strong, the difference is not statistically significant. Conclusion:using montelukast com-bined with salmeterol and fluticasone propionate on asthma treatment, oral administration of former, inhaling small doses of the latter, and clinical efficacy and the regular doses of salmeterol and fluticasone propionate in the treatment of difference was not statistically significant, had the same safety and effectiveness.